Author:
Ray Arghya,Song Yan,Chauhan Dharminder,Anderson Kenneth C.
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Kane, R. C., Bross, P. F., Farrell, A. T. & Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 8, 508–513 (2003).
2. Richardson, P. Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. Oncology 17, 1063–1065 (2003).
3. Anderson, K. C. Therapeutic advances in relapsed or refractory multiple myeloma. J. Natl Compr. Cancer Netw. 11(5 Suppl), 676–679 (2013).
4. Lonial, S. et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 106, 3777–3784 (2005).
5. Franke, N. E. et al. Impaired bortezomib binding to mutant ß5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 26, 757–768 (2012).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献